CYP3A4 and COVID-19: A pharmacokinetic study has shown that the potent inhibition of CYP1A and CYP3A by QPD partially blocks the formation of the oxidative metabolites of arachidonic acid, thereby alleviating systemic inflammation in patients with COVID-19.